文献速递腹部技术与安全CT

可切除胰腺导管腺癌术前影像组学预后模型的外部验证研究

Pre-operative radiomics model for prognostication in resectable pancreatic adenocarcinoma with external validation.
PubMed 文献 · Eur Radiol · 2021-11-10

该回顾性国际多中心研究在352例加拿大五家医院训练队列中构建可切除胰腺导管腺癌术前临床-影像组学预后模型,并在215例爱尔兰34家医院队列中外部验证。影像组学特征可预测总生存和无病生存,临床-影像组学模型C统计量0.545高于临床模型0.497和TNM模型0.525,但多数阈值概率下临床效用有限。

要点

  • 影像组学特征在外部验证队列中预测总生存的校正HR为2.87(95%CI 1.40-5.87,p<0.001)。
  • 影像组学特征预测无病生存的校正HR为5.28(95%CI 2.35-11.86,p<0.001)。
  • 临床-影像组学模型C统计量0.545高于临床模型0.497和TNM模型0.525,但多数阈值概率下临床效用有限。

核心结论

  • 多机构术前临床-影像组学模型在外部验证中较临床模型显示更高净获益,但临床效用有限,反映影像组学在真实世界用于PDAC预后判断的固有局限。

研究设计与样本

  • 回顾性国际多中心研究,训练队列352例可切除PDAC患者,术前CT来自加拿大五家医院。
  • 外部验证队列215例,术前CT来自爱尔兰34家医院。
  • 构建Cox模型:术前临床变量模型、临床+CT影像组学模型、术后TNM模型作为参照。
  • 结局指标为总生存和无病生存,采用C统计量、校准和决策曲线分析评估模型。

诊断标准与关键数值

  • 影像组学特征预测总生存的校正HR为2.87(95%CI 1.40-5.87,p<0.001),预测无病生存的校正HR为5.28(95%CI 2.35-11.86,p<0.001)。
  • 年龄预测总生存的校正HR为1.02(95%CI 1.01-1.04,p=0.01),预测无病生存的校正HR为1.02(95%CI 1.00-1.04,p=0.03)。
  • 外部验证队列中,高风险组与低风险组中位总生存分别为22.9个月和37个月(p=0.0092),中位无病生存分别为14.2个月和29.8个月(p=0.0023)。
  • 外部验证队列校准中等,总生存3年和5年的平均绝对误差分别为7%和13%。
  • 临床-影像组学模型C统计量0.545(95%CI 0.543-0.546)高于临床模型0.497(95%CI 0.496-0.499,p<0.001)和TNM模型0.525(95%CI 0.524-0.526,p<0.001)。

临床应用与阅片要点

  • 临床-影像组学模型较临床模型显示更高净获益,但多数阈值概率下临床效用有限。
  • 模型判别能力和临床效用仍低,可能因CT采集参数异质性所致。
  • 未来研究应聚焦CT协议和采集参数的标准化。

局限性

  • 外部验证中临床-影像组学模型在多数阈值概率下临床效用有限。
  • 模型校准中等,总生存3年和5年平均绝对误差分别为7%和13%。
  • 判别能力和临床效用低可能归因于CT采集参数的异质性。
  • 尽管影像组学方法先进,PDAC预后判断仍具挑战性,主要因其判别能力低。
  • 未来研究应聚焦CT协议和采集参数的标准化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: In resectable pancreatic ductal adenocarcinoma (PDAC), few pre-operative prognostic biomarkers are available. Radiomics has demonstrated potential but lacks external validation. We aimed to develop and externally validate a pre-operative clinical-radiomic prognostic model.

METHODS: Retrospective international, multi-center study in resectable PDAC. The training cohort included 352 patients (pre-operative CTs from five Canadian hospitals). Cox models incorporated (a) pre-operative clinical variables (clinical), (b) clinical plus CT-radiomics, and (c) post-operative TNM model, which served as the reference. Outcomes were overall (OS)/disease-free survival (DFS). Models were assessed in the validation cohort from Ireland (n = 215, CTs from 34 hospitals), using C-statistic, calibration, and decision curve analyses.

RESULTS: The radiomic signature was predictive of OS/DFS in the validation cohort, with adjusted hazard ratios (HR) 2.87 (95% CI: 1.40-5.87, p < 0.001)/5.28 (95% CI 2.35-11.86, p < 0.001), respectively, along with age 1.02 (1.01-1.04, p = 0.01)/1.02 (1.00-1.04, p = 0.03). In the validation cohort, median OS was 22.9/37 months (p = 0.0092) and DFS 14.2/29.8 (p = 0.0023) for high-/low-risk groups and calibration was moderate (mean absolute errors 7%/13% for OS at 3/5 years). The clinical-radiomic model discrimination (C = 0.545, 95%: 0.543-0.546) was higher than the clinical model alone (C = 0.497, 95% CI 0.496-0.499, p < 0.001) or TNM (C = 0.525, 95% CI: 0.524-0.526, p < 0.001). Despite superior net benefit compared to the clinical model, the clinical-radiomic model was not clinically useful for most threshold probabilities.

CONCLUSION: A multi-institutional pre-operative clinical-radiomic model for resectable PDAC prognostication demonstrated superior net benefit compared to a clinical model but limited clinical utility at external validation. This reflects inherent limitations of radiomics for PDAC prognostication, when deployed in real-world settings.

KEY POINTS: • At external validation, a pre-operative clinical-radiomics prognostic model for pancreatic ductal adenocarcinoma (PDAC) outperformed pre-operative clinical variables alone or pathological TNM staging. • Discrimination and clinical utility of the clinical-radiomic model for treatment decisions remained low, likely due to heterogeneity of CT acquisition parameters. • Despite small improvements, prognosis in PDAC using state-of-the-art radiomics methodology remains challenging, mostly owing to its low discriminative ability. Future research should focus on standardization of CT protocols and acquisition parameters.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Healy GM, Salinas-Miranda E, Jain R, et al. Pre-operative radiomics model for prognostication in resectable pancreatic adenocarcinoma with external validation. Eur Radiol. 2021. PMID: 34757450. doi:10.1007/s00330-021-08314-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。